Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492381 | 0.94 | CCR1 (1.00) | CCR1LMNATSHRKMT2ANR1I2 | |
| SCHEMBL4492389 | 0.94 | CCR1 (1.00) | CCR1LMNATSHRKMT2ANR1I2 | |
| Trifluoroacetic Acid SCHEMBL5460375 | 0.84 | CCR1 (0.64) | CCR1 | |
| SCHEMBL4507643 | 0.80 | CCR1 (0.74) | CCR1 | |
| SCHEMBL4507638 | 0.80 | CCR1 (0.74) | CCR1 | |
| Trifluoroacetic Acid SCHEMBL5451754 | 0.80 | CCR1 (0.56) | CCR1 | |
| Trifluoroacetic Acid SCHEMBL5451751 | 0.79 | CCR1 (0.61) | CCR1 | |
| SCHEMBL4503484 | 0.78 | CCR1 (0.72) | CCR1 | |
| SCHEMBL4503478 | 0.78 | CCR1 (0.72) | CCR1 | |
| SCHEMBL4497465 | 0.77 | CCR1 (0.67) | CCR1KMT2ANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCR1 | CCR1 3/4885LMNA 4043/4885TSHR 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.